Italiano
EnglishToday we are a great international Group: our history started many years ago
Foundation of Sorin, a nuclear energy production research site in Saluggia (VC; Italy); with the Joint Venture between FIAT and Montecatini: The first in In Vitro Diagnostic (IVD) business is developed, focused on the European market.
DiaSorin is sold to the multinational group American Standard International
In 2000 DiaSorin completes a Management Buyout, backed by Finde Group (today IP Investimenti e Partecipazioni) and other financial and industrial investors
DiaSorin acquires BYC Sangtec and the related rights for LIAISON, the first CLIA immunodiagnostic platform of DiaSorin Group, and starts the conversion of the tests previously developed with ELISA technology on the most recent and automated CLIA
On July 19, 2007 the DiaSorin title debuts at Piazza Affari
Acquisition of Biotrin company
We want to reach everyone, wherever they are
We have progressively expanded our geographical presence on a global scale. Starting from our historical reference markets in Europe and in the United States, we opened new commercial branches in the main markets, thus becoming a real global player in the sector with a presence in more than 120 countries.
Acquisitions, partnerships and commercial agreements to grow and improve the quality and offer of our diagnostic solutions
Research and distribution agreement with Meridian Inc. for the development of tests for gastrointestinal infections
Acquisition of the Murex product line
Agreement with Precision System Science (LIAISON Iam development), Eiken Chemical (Q-LAMP development), Cardinal Health (distribution agreement on the USA market)
Launch of the LIAISON XL
Acquisition of Nordiag
Joint venture with Trivitron in the Indian market
Agreement with Roche to allow the connectivity of the LIAISON XL system to the cobas 8100 of Roche
Strategic commercial agreement for Hepatitis and HIV tests in China with Beckman Coulter, extended the following year to the USA
In 2016, the acquisition of Focus Diagnostics’ business unit enabled the Group to expand its activities in molecular diagnostics, a quickly growing segment of the in vitro diagnostic market.
Partnership with Qiagen to offer a fully automated solution for the diagnosis of tuberculosis with QuantiFERON-TB Gold Plus test available on the LIAISON analyzers
Siemens Healthineers ELISA business acquisition
Partnership with Meridian for the distribution of the Helicobacter Pylori test in the USA and UK and the development of new tests of the intestinal panel
DiaSorin shares enter the FTSE MIB index
Commercial launch of LIAISON® XS Approval of Latent Tuberculosis Test in the USA
Acquisition of TTP technology for point-of-care molecular diagnostic solutions
Launch of a molecular and immuno test for COVID-19
We always want to be at the forefront, striving for excellence
Our growth continues with the aim of strengthening our position as leader in the immunodiagnostics segment and of expanding our presence in molecular diagnostics.
This is why we are recognized as the Diagnostic Specialist.
